Illumina, Inc. (NASDAQ:ILMN) Receives Average Recommendation of “Hold” from Analysts

Illumina, Inc. (NASDAQ:ILMN) has been given a consensus rating of “Hold” by the nineteen brokerages that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $127.9412.

Several research firms recently commented on ILMN. UBS Group reissued a “neutral” rating and issued a $135.00 price objective on shares of Illumina in a research note on Friday, February 6th. Stifel Nicolaus increased their target price on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Barclays raised their price target on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. Canaccord Genuity Group upped their price objective on shares of Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research note on Monday, January 26th. Finally, Robert W. Baird set a $137.00 price objective on shares of Illumina in a report on Friday, February 6th.

Insider Buying and Selling at Illumina

In related news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider directly owned 17,887 shares in the company, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Patricia Leckman sold 2,370 shares of Illumina stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.17% of the stock is owned by insiders.

Institutional Trading of Illumina

A number of hedge funds and other institutional investors have recently made changes to their positions in ILMN. Capital World Investors raised its stake in shares of Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after acquiring an additional 3,331,542 shares during the period. Invesco Ltd. increased its holdings in Illumina by 97.0% in the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock valued at $360,426,000 after purchasing an additional 1,352,731 shares during the last quarter. AQR Capital Management LLC raised its position in Illumina by 55.3% in the second quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock valued at $313,290,000 after purchasing an additional 1,174,295 shares during the period. Morgan Stanley raised its position in Illumina by 66.0% in the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock valued at $331,710,000 after purchasing an additional 1,005,474 shares during the period. Finally, Nordea Investment Management AB lifted its stake in Illumina by 2,792.2% during the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after purchasing an additional 911,843 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 2.4%

ILMN opened at $120.54 on Tuesday. The company has a market cap of $18.43 billion, a PE ratio of 22.12, a price-to-earnings-growth ratio of 2.25 and a beta of 1.45. Illumina has a twelve month low of $68.70 and a twelve month high of $155.53. The company has a 50-day moving average price of $135.52 and a 200 day moving average price of $117.54. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Sell-side analysts expect that Illumina will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.